Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects

J A Nightingale, D F Rogers, L A Hart, S A Kharitonov, K F Chung, P J Barnes, J A Nightingale, D F Rogers, L A Hart, S A Kharitonov, K F Chung, P J Barnes

Abstract

Background: Inhalation of lipopolysaccharide (LPS) causes an inflammatory response in the lungs. To explore this response, inflammatory indices were measured in induced sputum from atopic asthmatic patients and compared with atopic and non-atopic subjects after inhalation of LPS.

Methods: The effects of inhaled LPS (60 micrograms) or placebo (0.9% saline) were examined in a randomised, double blind, crossover trial in 11 non-atopic normal subjects, seven atopic, non-asthmatic individuals, and eight atopic, asthmatic patients. Sputum was induced by inhalation of 3.5% saline before the test inhalation and again at six hours and 24 hours. Spirometry (forced expiratory volume in one second (FEV1), forced vital capacity (FVC)), heart rate, blood pressure, and temperature were recorded before challenge and at intervals until eight hours, and at 24 hours after challenge.

Results: There was no change in cardiovascular parameters or spirometry with either exposure in any group. In the asthmatic patients only, inhalation of LPS caused a rise in temperature, with a peak of 0.6 degree C at seven hours, which was significantly higher than following placebo inhalation (p < 0.05). In normal subjects, LPS caused a significant rise in absolute neutrophil counts at 24 hours compared with placebo (median 1.1 x 10(6) cells/ml after LPS; median 0.2 x 10(6) cells/ml after placebo, p < 0.01), but no change in differential counts. In asthmatic patients, LPS caused a significant rise in differential neutrophil counts at six hours compared with placebo (median 88% after LPS; median 56% after placebo, p < 0.05), but no change in absolute cell counts at any time point. There was no change in neutrophil counts in the atopic subjects. There was a significant rise in sputum interleukin 8 (IL-8) concentrations in normal subjects at six hours compared with placebo (mean placebo 1.1 ng/ml; LPS 3.0 ng/ml, p < 0.05) and in asthmatics at 24 hours (mean placebo 2.0 ng/ml, LPS 6.9 ng/ml, p < 0.05). There were no changes in sputum concentrations of tumour necrosis factor alpha or granulocyte macrophage colony stimulating factor at any time.

Conclusions: Inhalation of LPS causes a neutrophilic inflammation with increases in IL-8 in both normal and asthmatic subjects.

References

    1. Br J Ind Med. 1969 Oct;26(4):314-21
    1. J Allergy Clin Immunol. 1989 May;83(5):882-7
    1. Ann Intern Med. 1975 Sep;83(3):355-7
    1. Eur J Respir Dis Suppl. 1982;123:34-46
    1. Chest. 1983 Oct;84(4):403-7
    1. Infect Immun. 1984 Jan;43(1):206-12
    1. Clin Allergy. 1984 Jan;14(1):109-12
    1. Eur J Respir Dis. 1984 May;65(4):266-71
    1. Br J Ind Med. 1986 May;43(5):327-31
    1. Blood. 1987 Feb;69(2):682-91
    1. Blood. 1988 Oct;72(4):1368-74
    1. Br J Ind Med. 1989 Jan;46(1):31-7
    1. J Clin Lab Immunol. 1988 Oct;27(2):83-6
    1. Am Rev Respir Dis. 1989 Oct;140(4):981-6
    1. Am J Ind Med. 1990;17(1):1-148
    1. Am Rev Respir Dis. 1990 Mar;141(3):683-8
    1. J Infect Dis. 1992 Apr;165(4):689-94
    1. Thorax. 1992 Apr;47(4):288-91
    1. Chest. 1992 Oct;102(4):1095-8
    1. Eur Respir J. 1992 Sep;5(8):992-6
    1. Am J Respir Cell Mol Biol. 1993 Jan;8(1):28-34
    1. Am Rev Respir Dis. 1992 Aug;146(2):352-7
    1. J Leukoc Biol. 1995 Apr;57(4):624-34
    1. Clin Exp Allergy. 1995 Jan;25(1):73-9
    1. Eur Respir J. 1995 Sep;8(9):1566-71
    1. Am J Respir Crit Care Med. 1996 Feb;153(2):530-4
    1. Chest. 1996 Jul;110(1):263-70
    1. Am J Respir Cell Mol Biol. 1996 Jul;15(1):64-70
    1. Arch Toxicol. 1996;70(3-4):230-6
    1. J Lab Clin Med. 1997 Jan;129(1):106-14
    1. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1157-64
    1. Thorax. 1998 Feb;53(2):87-90
    1. J Appl Physiol (1985). 1989 Mar;66(3):1059-64
    1. J Allergy Clin Immunol. 1975 Oct;56(4):323-7

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅